Calliditas Therapeutics Ab's ROA from the second quarter of 2024 to the second quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Calliditas Therapeutics Ab's ROA in the second quarter of 2024?
Calliditas Therapeutics Ab recorded a cumulative net loss of $-63 million during 12 months ending in the second quarter of 2024, resulting in a negative return on assets (ROA) of -33.12%.

However, within the Healthcare sector 446 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the fourth quarter of 2023 from to 4458.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2024) II. Quarter	(Dec 31 2023) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter
Y / Y Total Assets Change	-17.53 %	-84.8 %	-34.98 %	-34.98 %	-34.98 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-63	-59	-53	-53	-64
Return On Assets (TTM)	-33.12 %	-29.44 %	-11.09 %	-10.5 %	-12 %
CALT's Total Ranking	# 4458	#	#	#	# 4783
Total Assets (TTM) in million	165	200	200	200	200
Seq. Total Assets Change	-17.53 %	0 %	0 %	0 %	-84.8 %
Seq. Net Income Change	-	-	-	-	-

CALT's 5 Years Annual ROA >> Back to CALT Management Effectiveness >> Compare CALT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 171
Sector	# 447
Overall	# 4364

Return On Assets Statistics
High	Average	Low
-23.64 %	-24.36 %	-25.07 %
(Dec 31 2022)		(Dec 31 2023)

Financial Statements
Calliditas Therapeutics Ab's Assets	$ 165 million	CALT's Balance sheet
Calliditas Therapeutics Ab's Income	$ -4 million	Quarterly CALT's Income Statement
CALT's Income by Division		See CALT's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2018) FY 2020	FY
Y / Y Total Assets Change	-34.98 %	15.17 %	195.02 %	-	-
Total Assets in million	200	307	267	90	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-50	-44	0	-15	0
Annual Return On Assets	-25.07 %	-14.42 %	0 %	-16.82 %	-

CALT's 5 Years Annual ROA >> Back to CALT Management Effectiveness >> Compare CALT ROA to its Competitors

More Return On Assets Ratios
CALT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CALT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CALT's Competitors
Subscribers only: Roa for Calliditas Therapeutics Ab's Suppliers
Subscribers only: Return On Assets for CALT's Customers

You may also want to know
CALT's Roi	CALT's Inventory Turnover Ratio	CALT's Growth Rates	CALT's Dividend Comparisons
	CALT's Profitability Ratios	CALT's Asset Turnover Ratio	CALT's Dividend Growth
CALT's Roe	CALT's Valuation Ratios	CALT's Financial Strength Ratios	CALT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-18T15:50:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.